Without accountability to prioritize health outcomes of minority populations, there cannot be true progress toward health equity. Many biomedical investigators recognize the paramount importance of health equity, yet progress has been slow. In this session panelists will identify those who are accountable for ensuring health equity goals are met. They will examine how progress is defined and measured, and where the funding for these accountability and equity initiatives can be found and sustained. Session participants will also discuss the internal and external metrics for justifying the funding of these programs. They will assess what—if anything—changes in the absence of external drivers of social responsibility, such as lessened pressure from regional or federal governments. 

Moderator

Yasmeen Long

Director, FasterCures, Milken Institute

Speakers

Kevin Bugin

Deputy Director of Operations, Office of New Drugs, US Food and Drug Administration

Sally Okun

Executive Director, Clinical Trials Transformation Initiative

John Wigneswaran

Chief Medical Officer, Walmart